| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.38.10.2270 |
| P8608 | Fatcat ID | release_kpnwncrdjnfxfh4mvs4vfa6cti |
| P932 | PMC publication ID | 284729 |
| P698 | PubMed publication ID | 7840556 |
| P2093 | author name string | J Ticehurst | |
| D M Ryan | |||
| C R Penn | |||
| M H Dempsey | |||
| P2860 | cites work | 4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro | Q28378588 |
| Rational design of potent sialidase-based inhibitors of influenza virus replication | Q29616647 | ||
| Sensitive radioimmunoassay for the broad-spectrum antiviral agent ribavirin | Q30451335 | ||
| Plaque inhibition assay for drug susceptibility testing of influenza viruses | Q33729018 | ||
| Genetic basis of resistance to rimantadine emerging during treatment of influenza virus infection | Q36866575 | ||
| Lessons for human influenza from pathogenicity studies with ferrets | Q39634875 | ||
| Ribavirin and inosiplex: a review of their present status in viral diseases | Q40100883 | ||
| The relative potencies of anti-influenza compounds | Q40560066 | ||
| Response of influenza virus-infected mice to selected doses of ribavirin administered intraperitoneally or by aerosol | Q40617590 | ||
| THE IN VIVO ANTIVIRAL ACTIVITY OF 1-ADAMANTANAMINE (AMANTADINE). I. PROPHYLACTIC AND THERAPEUTIC ACTIVITY AGAINST INFLUENZA VIRUSES. | Q43210715 | ||
| The use of an animal model to study transmission of influenza virus infection | Q45810360 | ||
| Absorption, distribution and excretion of amantadine hydrochloride | Q69981277 | ||
| Uptake, metabolism and excretion of orally and intravenously administered, double-labeled N-glycoloylneuraminic acid and single-labeled 2-deoxy-2,3-dehydro-N-acetylneuraminic acid in mouse and rat | Q70511222 | ||
| PASSIVE INTERFERON PROTECTION IN MOUSE INFLUENZA | Q76673084 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2270-5 | |
| P577 | publication date | 1994-10-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase) | |
| P478 | volume | 38 |
| Q36452689 | A chemically programmed antibody is a long-lasting and potent inhibitor of influenza neuraminidase |
| Q52081265 | A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration. |
| Q74489921 | Anti-influenza drugs and neuraminidase inhibitors |
| Q28378984 | Anti-influenza virus activities of 4-substituted 2,4-dioxobutanoic acid inhibitors |
| Q33730165 | Approaches and strategies for the treatment of influenza virus infections |
| Q24655526 | CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity |
| Q37409848 | CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract |
| Q35882160 | Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. |
| Q28369317 | Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. |
| Q35857200 | Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en |
| Q28343667 | Chemoprophylaxis of influenza A virus infections, with single doses of zanamivir, demonstrates that zanamivir is cleared slowly from the respiratory tract |
| Q30482353 | Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus |
| Q36181153 | Development of antivirals against influenza |
| Q27760264 | Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase |
| Q56675602 | Drugs for chemotherapy and prophylaxis of influenza: Mechanisms, efficacy, and safety (a review) |
| Q24567591 | Efficacy of novel hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 against human parainfluenza viruses in vitro and in vivo |
| Q33981934 | Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals |
| Q36396088 | Exacerbation of influenza virus infections in mice by intranasal treatments and implications for evaluation of antiviral drugs |
| Q35169692 | Experimental models of pulmonary infection |
| Q35120465 | GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets |
| Q39557208 | Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071. |
| Q45743964 | Immunological effects of the orally administered neuraminidase inhibitor oseltamivir in influenza virus-infected and uninfected mice |
| Q34083704 | In vitro and in vivo assay systems for study of influenza virus inhibitors |
| Q35134265 | In vivo anti-influenza virus activity of a zinc finger peptide |
| Q43247402 | Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue |
| Q79340361 | Influenza virus resistance to neuraminidase inhibitors |
| Q33922846 | Influenza virus sialidase: a target for drug discovery. |
| Q44408154 | Influenza virus virulence and its molecular determinants |
| Q41042625 | Inhibition of influenza virus infections in mice by GS4104, an orally effective influenza virus neuraminidase inhibitor |
| Q58573517 | Investigating Different Mechanisms of Action in Combination Therapy for Influenza |
| Q30352319 | Neuraminidase inhibitors and their potential use in the avian influenza pandemic |
| Q30472797 | New approaches to influenza chemotherapy. Neuraminidase inhibitors |
| Q28379409 | Oral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infection |
| Q39651456 | Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection |
| Q35138108 | Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. |
| Q48549976 | Prophylaxis and treatment of influenza encephalitis in an experimental mouse model |
| Q40943840 | Recent development in the design of antiviral agents |
| Q30304110 | Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. |
| Q44947544 | Saturation transfer difference (STD) 1H-NMR experiments and in silico docking experiments to probe the binding of N-acetylneuraminic acid and derivatives to Vibrio cholerae sialidase |
| Q44420217 | Semi-quantitative detection of viral RNA in influenza A virus-infected mice for evaluation of antiviral compounds |
| Q35627901 | Spotlight on zanamivir in influenza |
| Q73497825 | Summary of the II international consensus symposium on combined antiviral therapy and implications for future therapies |
| Q44363638 | Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir |
| Q44061381 | Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives |
| Q44061376 | Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives |
| Q44061378 | Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir |
| Q27000668 | Using the Ferret as an Animal Model for Investigating Influenza Antiviral Effectiveness |
| Q55441775 | Zanamivir Diminishes Lung Damage in Influenza A Virus-infected Mice by Inhibiting Nitric Oxide Production. |
| Q33978456 | Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies |
| Q54138583 | Zanamivir. |
| Q30327955 | Zanamivir: a rational approach to influenza B. |
| Q33748023 | Zanamivir: a review of clinical safety |
| Q34492611 | Zanamivir: an update of its use in influenza |
| Q28344586 | Zanamivir: from drug design to the clinic |
Search more.